Volatility Grows in Biotech Sector -- Keryx and AVI BioPharma Need to Put Up Results
October 21 2011 - 8:16AM
Marketwired
Drug approvals from administrative bodies in both the U.S. and
Europe have been pivotal for biotech companies recently. Investors
have been particularly sensitive to decisions made on new drugs
considering the state of the global economic recovery. The Bedford
Report examines investing opportunities in the Biotechnology
Industry and provides equity research on Keryx Biopharmaceuticals,
Inc. (NASDAQ: KERX) and AVI BioPharma Inc. (NASDAQ: AVII). Access
to the full company reports can be found at:
www.bedfordreport.com/KERX
www.bedfordreport.com/AVII
While there are some success stories in the industry, a number
of players are having trouble dealing with the volatile nature of
biotechnologies. Research and development costs are extremely high,
and the success of a product can sometimes not be measured until
late in development. According to Krishan Maggon, a Geneva-based
pharmaceuticals consultant, the number of new biotech drugs
approved in the U.S. has remained in the 20 to 25 range during the
past four years, while in Europe the figure was a record-low 14
last year.
The Bedford Report releases regular market updates on the
biotechnology industry so investors can stay ahead of the crowd and
make the best investment decisions to maximize their returns. Take
a few minutes to register with us free at www.bedfordreport.com and
get exclusive access to our numerous analyst reports and industry
newsletters.
Keryx Biopharmaceuticals said that an independent monitoring
board recommended that its late-stage study of a potential
colorectal cancer treatment continue as planned until it is
completed. The company is studying perifosine in patients with an
advanced form of the disease. The study has enrolled more than 465
patients nationwide, and it will measure the safety and
effectiveness of perifosine plus another treatment, capecitabine,
compared to a combination of a placebo and capecitabine in people
who have had a previous treatment fail.
AVI BioPharma is focused on the discovery and development of
novel RNA-based therapeutics for rare and infectious diseases, as
well as other select disease targets. For the second quarter of
2011 AVI reported an operating loss of $10.1 million compared with
an operating loss of $7.7 million in the second quarter of
2010.
The Bedford Report provides Market Research focused on equities
that offer growth opportunities, value, and strong potential
return. We strive to provide the most up-to-date market activities.
We constantly create research reports and newsletters for our
members. The Bedford Report has not been compensated by any of the
above mentioned publicly traded companies. The Bedford Report is
compensated by other third party organizations for advertising
services. We act as an independent research portal and are aware
that all investment entails inherent risks. Please view the full
disclaimer at http://www.bedfordreport.com/disclaimer
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: The Bedford Report Email Contact
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From May 2024 to Jun 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2023 to Jun 2024